Published in Annu Rev Med on January 01, 2009
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
MicroRNAs associated with metastatic prostate cancer. PLoS One (2011) 1.66
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res (2009) 1.04
Toxin-based therapeutic approaches. Toxins (Basel) (2010) 1.00
Microdevices integrating affinity columns and capillary electrophoresis for multibiomarker analysis in human serum. Lab Chip (2010) 0.99
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer (2014) 0.98
Prostate cancer - a biomarker perspective. Front Endocrinol (Lausanne) (2012) 0.97
Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis (2012) 0.92
Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status. Prostate Cancer Prostatic Dis (2009) 0.89
Electrochemical, Electrochemiluminescence, and Photoelectrochemical Aptamer-Based Nanostructured Sensors for Biomarker Analysis. Biosensors (Basel) (2016) 0.86
Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): potential role as a biomarker in prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.86
A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. Oncol Lett (2012) 0.85
The present and future of prostate cancer urine biomarkers. Int J Mol Sci (2013) 0.85
Proteomics of microparticles with SILAC Quantification (PROMIS-Quan): a novel proteomic method for plasma biomarker quantification. Mol Cell Proteomics (2015) 0.84
Emerging roles of human prostatic Acid phosphatase. Biomol Ther (Seoul) (2013) 0.84
Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment. BMC Cancer (2014) 0.83
Prostate cancer: the need for biomarkers and new therapeutic targets. J Zhejiang Univ Sci B (2014) 0.82
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer (2014) 0.82
Appropriateness of Prostate Cancer Imaging among Veterans in a Delivery System without Incentives for Overutilization. Health Serv Res (2015) 0.82
Clinically available RNA profiling tests of prostate tumors: utility and comparison. Asian J Androl (2016) 0.81
Identification of an antibody fragment specific for androgen-dependent prostate cancer cells. BMC Biotechnol (2014) 0.80
Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients. J Transl Med (2011) 0.79
Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer. Proteome Sci (2015) 0.79
Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers. Anal Chem (2011) 0.78
Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer. Asian J Androl (2012) 0.77
PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer. Turk J Urol (2014) 0.77
Novel biomarkers for the detection of prostate cancer. J Clin Urol (2016) 0.77
Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer. PLoS One (2015) 0.76
The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-(13)C]-ketoisocaproate. Magn Reson Imaging (2014) 0.76
Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer. BMC Cancer (2017) 0.75
Highlights from the prostate cancer genome report. Asian J Androl (2011) 0.75
Identification of microRNA signature and potential pathway targets in prostate cancer. Exp Biol Med (Maywood) (2016) 0.75
Multiplexed detection of molecular biomarkers with phase-change nanoparticles. Nanomedicine (Lond) (2013) 0.75
Integration of gene chip and topological network techniques to screen a candidate biomarker gene (CBG) for predication of the source water carcinogenesis risks on mouse Mus musculus. Ecotoxicology (2011) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Delay of surgery in men with low risk prostate cancer. J Urol (2011) 3.05
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32
National trends in the utilization of partial nephrectomy before and after the establishment of AUA guidelines for the management of renal masses. Urology (2013) 2.28
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27
Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst (2013) 2.20
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology (2008) 2.04
Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol (2013) 2.01
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol (2004) 1.95
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
Early identification of individuals with prostate cancer in negative biopsies. J Urol (2004) 1.78
Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol (2009) 1.77
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol (2007) 1.72
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology (2011) 1.71
The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. J Biol Chem (2011) 1.68
Nuclear matrix protein alterations associated with colon cancer metastasis to the liver. Clin Cancer Res (2002) 1.65
Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology (2010) 1.64
Validation of the partin nomogram for prostate cancer in a national sample. J Urol (2010) 1.64
Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol (2010) 1.64
Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol (2008) 1.63
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology (2013) 1.63
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology (2003) 1.62
Prostate specific antigen testing among the elderly--when to stop? J Urol (2009) 1.62
Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols. Urology (2009) 1.62
Causes of death after radical prostatectomy at a large tertiary center. J Urol (2012) 1.61
Under diagnosis and over diagnosis of prostate cancer. J Urol (2007) 1.61
Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy. Prostate (2010) 1.60
Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. J Urol (2012) 1.59
Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int (2010) 1.58
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila) (2012) 1.57
Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology (2002) 1.56
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int (2013) 1.55
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate (2008) 1.53
Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A (2002) 1.53
Retracted Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res (2008) 1.51
Contemporaneous comparison of open vs minimally-invasive radical prostatectomy for high-risk prostate cancer. BJU Int (2013) 1.48
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology (2005) 1.48
Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. J Urol (2002) 1.47
The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted. J Urol (2010) 1.47
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate (2013) 1.46
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res (2005) 1.46
Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer (2008) 1.46
Free prostate-specific antigen in serum is becoming more complex. Urology (2002) 1.46
Standardization of two immunoassays for human glandular kallikrein 2. Clin Chem (2003) 1.45
Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. Urology (2010) 1.44
Applying complexed prostate-specific antigen to clinical practice. Urology (2004) 1.44
Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol (2002) 1.43
Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate (2004) 1.43
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol (2006) 1.42
Trends in immediate perioperative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20-year institutional experience. BJU Int (2013) 1.42
Modeling grade progression in an active surveillance study. Stat Med (2013) 1.41